Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. New York University Langone Medical Center, New York, NY, United States

Survival: 14.5 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: New York University Langone Medical Center
Journal: Link
Date: 3/2011

This study involved 111 patients with peripheral T-cell lymphoma (a subtype of non-Hodgkin’s lymphoma). The average patient age was 57.7 years and 68% were male.

Patients were treated with the biologic therapy agent pralatrexate, which is an inhibitor of a protein (dihydrofolate reductase) involved in cell growth.

There was one treatment-related death due to cardiopulmonary arrest (heart attack). Grade 4 mucositis (inflammation of the lining of the mouth and digestive tract), thrombocytopenia, and neutropenia were also reported.

The median overall survival was 14.5 months.

Several of the authors were supported or employed by Allos Therapeutics, Inc., the makers of pralatrexate.

Correspondence: Dr. Owen A.O’Connor; email: owen.o’

E-mail to a Friend Email Physician More Information